Syngene Extends Research Collaboration with Bristol Myers Squibb to 2035
Filing Summary
Syngene International Ltd. has extended its long-term research collaboration with Bristol Myers Squibb until 2035. This agreement broadens the scope of integrated services across the drug development lifecycle, including discovery, translational sciences, pharmaceutical development, and manufacturing. The collaboration, which began in 1998, has been instrumental in supporting Bristol Myers Squibb’s research and development efforts. The Biocon Bristol Myers Squibb Research and Development Center, established in 2009, plays a key role in this partnership. The center employs around 700 scientists and contributes to various therapeutic areas, including cardiovascular and oncology.
Syngene International Ltd. has announced the extension of its strategic collaboration with Bristol Myers Squibb until 2035. This partnership, which began in 1998, focuses on providing integrated services across the drug development lifecycle. The collaboration includes areas such as discovery, translational sciences, pharmaceutical development, and manufacturing. The agreement aims to facilitate seamless progression from research to commercialization.
The financial terms of the extended collaboration have not been disclosed in the filing. However, the partnership is expected to continue supporting Bristol Myers Squibb’s research and development initiatives. The collaboration has historically contributed to reducing development timelines and overall costs for Bristol Myers Squibb.
The scope of the collaboration covers a wide range of services. These include chemistry, biology, drug metabolism, pharmacokinetics, and clinical trials. The partnership also encompasses data and information technology services. This comprehensive approach aims to support Bristol Myers Squibb in advancing its drug development programs.
The Biocon Bristol Myers Squibb Research and Development Center (BBRC) is a key component of this collaboration. Established in 2009, the center employs around 700 scientists. It supports integrated capabilities across target identification, lead discovery, lead optimization, and pharmaceutical development. The center contributes to various therapeutic areas, including cardiovascular, fibrosis, immunology, and oncology.
The timeline for the collaboration extends through 2035. The BBRC has played a pivotal role in accelerating the progression of novel compounds from early discovery to first-in-human studies. This has helped reduce development timelines and overall costs for Bristol Myers Squibb. The center continues to be a major strategic R&D site for the company.
Bristol Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines. The company aims to address serious diseases and improve patient outcomes worldwide. Its collaboration with Syngene is part of its strategy to enhance research and development capabilities.
Syngene International Ltd. is a global contract research, development, and manufacturing organization. The company serves various sectors, including pharmaceuticals, biotechnology, and specialty chemicals. Syngene’s team of over 8,200 employees, including 5,600 scientists, provides integrated scientific and manufacturing solutions to global customers. The company focuses on delivering scientific excellence and robust data security to improve time-to-market and lower the cost of innovation.